Headlands Technologies’s Aurinia Pharmaceuticals AUPH Stock Holding History

Headlands Technologies’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Sell	61,791 -13,700	-18%	-$219K	0.11%	235
2026 Q1	$1.12M	Sell	75,491 -17,034	-18%	-$249K	0.13%	182
2025 Q4	$1.48M	Buy	92,525 +58,833	+175%	+$834K	0.12%	198
2025 Q3	$372K	Buy	+33,692	New	+$368K	0.03%	424
2025 Q1	–	Sell	-2,113	Closed	-$19K	–	1137
2024 Q4	$19K	Buy	+2,113	New	+$17.2K	﹤0.01%	937

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's AUPH Position: Q2 2026 in Review

Headlands Technologies reduced its Aurinia Pharmaceuticals (AUPH) stake by 18% in Q2 2026, selling an estimated $219K and leaving 61,791 shares worth $1.05M. The position accounts for 0.11% of the portfolio, ranked #235.

Headlands Technologies first reported a position in AUPH in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.48M in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Headlands Technologies held 61,791 shares of Aurinia Pharmaceuticals worth $1.05M as of Q2 2026.
Headlands Technologies sold 13,700 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $219K.
Aurinia Pharmaceuticals made up 0.11% of Headlands Technologies's portfolio in Q2 2026, its #235 holding.
Headlands Technologies first reported a position in Aurinia Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
Headlands Technologies's Aurinia Pharmaceuticals position peaked at $1.48M in Q4 2025.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.